Virax Biolabs Group Limited
VRAX · NASDAQ
9/30/2025 | 3/31/2025 | 9/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Market Cap | $3 | $5 | $6 | $2 |
| - Cash | $3 | $4 | $7 | $4 |
| + Debt | $1 | $0 | $1 | $0 |
| Enterprise Value | $0 | $1 | -$1 | -$2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 16.7% | -72.2% | -93.8% | – |
| Gross Profit | -$0 | -$0 | -$0 | $0 |
| % Margin | -13,396.4% | -3,381.2% | -130.7% | 50.1% |
| EBITDA | -$2 | -$3 | -$3 | -$4 |
| % Margin | -147,336.7% | -227,823.3% | -55,861.2% | -4,658.2% |
| Net Income | -$2 | -$3 | -$3 | -$4 |
| % Margin | -145,446% | -239,827.3% | -55,651.7% | -4,784.7% |
| EPS Diluted | -0.49 | -0.76 | -0.89 | -1.71 |
| % Growth | 35.5% | 14.6% | 48% | – |
| Operating Cash Flow | -$3 | -$3 | -$2 | -$3 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$3 | -$3 | -$2 | -$3 |